JP2025515098A - シトクロムbdオキシダーゼ阻害剤およびその使用 - Google Patents

シトクロムbdオキシダーゼ阻害剤およびその使用 Download PDF

Info

Publication number
JP2025515098A
JP2025515098A JP2024564935A JP2024564935A JP2025515098A JP 2025515098 A JP2025515098 A JP 2025515098A JP 2024564935 A JP2024564935 A JP 2024564935A JP 2024564935 A JP2024564935 A JP 2024564935A JP 2025515098 A JP2025515098 A JP 2025515098A
Authority
JP
Japan
Prior art keywords
compound
formula
independently
pharma
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024564935A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025515098A5 (cg-RX-API-DMAC7.html
Inventor
ジェイ ミラー,マービン
シー モラスキ,ギャレット
ペス,ケビン
ケイ,サシテラパニー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Montana State University – Bozeman
University of Notre Dame
Original Assignee
Montana State University – Bozeman
University of Notre Dame
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Montana State University – Bozeman, University of Notre Dame filed Critical Montana State University – Bozeman
Publication of JP2025515098A publication Critical patent/JP2025515098A/ja
Publication of JP2025515098A5 publication Critical patent/JP2025515098A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024564935A 2022-05-03 2023-05-03 シトクロムbdオキシダーゼ阻害剤およびその使用 Pending JP2025515098A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263337836P 2022-05-03 2022-05-03
US63/337,836 2022-05-03
PCT/US2023/066571 WO2023215803A2 (en) 2022-05-03 2023-05-03 Cytochrome bd oxidase inhibitors and uses thereof

Publications (2)

Publication Number Publication Date
JP2025515098A true JP2025515098A (ja) 2025-05-13
JP2025515098A5 JP2025515098A5 (cg-RX-API-DMAC7.html) 2026-05-18

Family

ID=88647199

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024564935A Pending JP2025515098A (ja) 2022-05-03 2023-05-03 シトクロムbdオキシダーゼ阻害剤およびその使用

Country Status (4)

Country Link
US (1) US20250282784A1 (cg-RX-API-DMAC7.html)
EP (1) EP4518867A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025515098A (cg-RX-API-DMAC7.html)
WO (1) WO2023215803A2 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117534677B (zh) * 2024-01-09 2024-03-12 广东省农业科学院农业质量标准与监测技术研究所 一类含亚胺的三环稠合杂环化合物及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7569580B2 (en) * 2004-06-03 2009-08-04 Rigel Pharmaceuticals, Inc. Heterotricyclic compounds for use as HCV inhibitors
CA2599992A1 (en) * 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. Acridine and quinoline dervatives as sirtuin modulators
WO2007144669A1 (en) * 2006-06-15 2007-12-21 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Pyrazolo[1,5-a]quinazolin-5(4h)-ones as inhibitors of poly(adp-ribose)polymerase (parp)
GB0701273D0 (en) * 2007-01-24 2007-02-28 Angeletti P Ist Richerche Bio New compounds
RU2378278C2 (ru) * 2008-01-24 2010-01-10 Андрей Александрович Иващенко ЗАМЕЩЕННЫЕ 3-СУЛЬФОНИЛ-[1,2,3]ТРИАЗОЛО[1,5-a]ПИРИМИДИНЫ-АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-HT6 РЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЕ
WO2009151561A2 (en) * 2008-06-12 2009-12-17 President And Fellows Of Harvard College Methods and compounds for antimicrobial intervention
AU2010295622A1 (en) * 2009-09-16 2012-05-10 Cylene Pharmaceuticals, Inc. Tricyclic compounds and pharmaceutical uses thereof
WO2018084809A1 (en) * 2016-11-02 2018-05-11 Nanyang Technological University Methods for the treatment or prevention of mycobacterial infections
JP7659269B2 (ja) * 2018-12-21 2025-04-09 ユニバーシティ・オブ・ノートル・ダム・デュ・ラック 抗酸菌症治療のためのbdオキシダーゼ阻害剤の発見
CN113354651B (zh) * 2020-07-30 2022-07-22 四川大学 吡唑并[1,5-a]喹唑啉衍生物及其在药物制备中的用途
CN117561258A (zh) * 2021-03-02 2024-02-13 唯久生物技术(苏州)有限公司 作为sos1抑制剂的新型取代的三环氮杂杂环
WO2023287730A1 (en) * 2021-07-13 2023-01-19 Recurium Ip Holdings, Llc Tricyclic compounds

Also Published As

Publication number Publication date
EP4518867A2 (en) 2025-03-12
EP4518867A4 (en) 2026-04-08
WO2023215803A3 (en) 2023-12-14
US20250282784A1 (en) 2025-09-11
WO2023215803A2 (en) 2023-11-09

Similar Documents

Publication Publication Date Title
JP7644517B2 (ja) Kras突然変異型タンパク質阻害剤
US9701681B2 (en) Fused ring heteroaryl compounds and their use as Trk inhibitors
US7402596B2 (en) Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
WO2020259679A1 (zh) 嘧啶并五元氮杂环类衍生物、其制备方法及其在医药上的应用
US11905247B2 (en) Compounds as neurokinin-1 receptor antagonists and uses thereof
EP3813834B1 (en) New crbn modulators
WO2018196677A1 (zh) 氟代烯丙胺衍生物及其用途
KR20210107046A (ko) 거대고리 화합물 및 질환 치료에서 이들의 용도
JP2022126780A (ja) ジアリール大員環化合物、医薬組成物及びその用途
TW202333670A (zh) 抑制並降解irak4的化合物及其藥物组合物和藥學上的應用
BR112014030284B1 (pt) Composto, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica
ES2875562T3 (es) Inhibidores bicíclicos de histona desacetilasa
EP3390374A1 (en) Hydroxyalkylamine- and hydroxycycloalkylamine-substituted diamine-arylsulfonamide compounds with selective activity in voltage-gated sodium channels
EP3291810B1 (en) Histone deacetylase inhibitors and compositions and methods of use thereof
CN110770242A (zh) 作为vanin抑制剂的杂芳族化合物
JP2016503003A (ja) ナンセンス突然変異抑制剤としてのピリミド[4,5−b]キノリン−4,5(3h,10h)−ジオン
JP7793763B2 (ja) Tyk2/jak1シュードキナーゼドメイン阻害剤としての化合物ならびに合成および使用方法
KR20240091048A (ko) 열 충격 단백질 90 억제제
TW202328122A (zh) 降解Bcl-2家族蛋白的化合物及其在醫藥上的應用
US20210269442A1 (en) Fused ring derivative used as fgfr4 inhibitor
CN113666922A (zh) 内磺酰胺化合物及其使用方法
EP4232431A1 (en) Compounds and compositions for treating conditions associated with lpa receptor activity
US20250282784A1 (en) Cytochrome bd oxidase inhibitors and uses thereof
US20190112316A1 (en) Thiazolo[3,2-a] pyrimidinone and other heterobicyclic pyrimidinone compounds for use in medical therapy
KR102941832B1 (ko) Cdk9 억제제 및 이의 용도

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260507

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260507